Recent insider trends for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of HTGM, the data has a lot to say about how the stock might perform going forward.
Institutions own 21.68% of HTG Molecular Diagnostics, Inc. (HTGM)’s shares. The total value of these holdings, in millions, is $6. Among active positions in the latest quarter, 10 holders increased their positions by a total of 157555 shares, 10 holders decreased the positions by a total of 659159 shares, and 5 holders held their positions. This works out to a net decrease in ownership of 501604 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 4 holders initiated new positions by a total of 71018 shares and 7 holders exited their positions by a total of 95708 shares. This nets out to a decrease of 24690 shares and is another bearish sign for HTGM.
In the last three months, insiders executed a total of 12 trades. 5 of these were buys and 7 were sells. Insider ownership decreased by a total of 1.21 million shares, which suggests that HTGM’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 15 buys and 8 sells, and ownership decreased by a net of 1.5 million shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)’s short interest is 1.76 million shares, or 50.88% of the float. This represents a decrease of -6% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Given what the insider ownership patterns are saying, it makes sense to consider the technicals to see if these pieces of information reach the same conclusion about the outlook for HTGM. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that HTGM is a buy, which implies that HTGM is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) is undervalued.